Tirosint-Sol - (13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 mcg/mL; Oral solution)

Generic Name	Levothyroxine Sodium	Innovator	IBSA
Dosage	13, 25, 50, 75, 88, 100, 112, 125, 137, 150, 175, 200 mcg/mL; Oral solution	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Tirosint is used as replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, or in the treatment or prevention of various types of euthyroid goiters, as an adjunct to surgery and radioiodine therapy in the management of thyrotripin-dependment well differentiated thyroid cancer.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
****** (*****)	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events